Abstract Mitochondria play a critical role in the cardiomyocyte physiology by generating majority of the ATP required for the contraction/relaxation through oxidative phosphorylation (OXPHOS). Aging is a major risk factor for cardiovascular diseases (CVD) and mitochondrial dysfunction has been proposed as potential cause of aging. Recent technological innovations in Seahorse XFe24 Analyzer enhanced the detection sensitivity of oxygen consumption rate and proton flux to advance our ability study mitochondrial function. Studies of the respiratory function tests in the isolated mitochondria have the advantages to detect specific defects in the mitochondrial protein function and evaluate the direct mitochondrial effects of therapeutic/ pharmacological agents. Here, we provide the protocols for studying the respiratory function of isolated murine cardiac mitochondria by measuring oxygen consumption rate using Seahorse XFe24 Analyzer. In addition, we provide details about experimental design, measurement of various respiratory parameters along with interpretation and analysis of data.
Introduction
Mitochondria, the power houses of the cells, generate ATP through oxidation of NADH and FADH 2 . Transfer of electrons from NADH to the oxygen through electron transport chain (ETC) is coupled with proton transfer across the inner mitochondrial membrane generating membrane potential. ATP synthase makes use of the proton gradient to generate ATP from ADP. The process of electron transfer to oxygen coupled with the formation of ATP is termed oxidative phosphorylation (OXPHOS). Reactive oxygen species (ROS) formed within the ETC, particularly at complex I and III, are considered to regulate cellular proliferation, differentiation, and apoptosis (Nunnari and Suomalainen 2012) . ROS generated from the mitochondria can lead to organelle dysfunction, contributing to age-related degenerative diseases (Nunnari and Suomalainen 2012) .
Aging is the main risk factor for cardiovascular diseases (CVD) (North and Sinclair 2012) . Notably, mitochondrial dysfunction plays a critical role in the cardiovascular aging (Dai et al. 2012) . It has been hypothesized that prolonged exposure to ROS causes mitochondrial dysfunction during aging (Dai et al. 2012 ) by inducing mtDNA mutations and oxidizing the mitochondrial proteins and lipids. Previous studies reported decreased complex I and III activities, state III respiration, and increase ROS generation in mitochondria from aged hearts (Dai et al. 2012 ). In addition, increased oxidative damage to mitochondrial proteins and DNA also has been shown in aged hearts and is proposed to play a key role cardiovascular aging (Herrero and Barja 2001; Martin-Fernandez and Gredilla 2016) . Furthermore, mice containing transgenic mitochondrial targeted catalase (mCAT mice) were found to have longer lifespan and protected from cardiovascular abnormalities observed with the aging (Dai et al. 2009 ). Interestingly, mitochondria from aged mCAT mice showed reduced aging-induced oxidative damage and DNA deletions (Dai et al. 2009 ). Similarly, the importance of mitochondria in cardiovascular aging is further supported by observations from mice with targeted mutations in mitochondrial polymerase gamma (Polg m/m ), enzyme involved in proof-reading of mtDNA (Trifunovic et al. 2004 ). These mice exhibited increased oxidative damage in cardiac mitochondria with increased cardiomyocyte apoptosis (Dai et al. 2010) . They exhibit cardiomyopathy with worsened age-related systolic and diastolic function (Dai et al. 2010) . In addition, the role of impaired mitochondrial function in aging is further supported by partial restoration of cardiac dysfunction in these mice when targeted with mCAT (Dai et al. 2010) . Moreover, consistent with the observations in transgenic mice, mitochondrial-targeted antioxidant proteins like SS-31 have been reported to ameliorate various age-related cardio and cerebrovascular diseases (Dai et al. 2012; Tarantini et al. 2018) . Furthermore, mitochondrial dysfunction is also known to play a key role in heart failure, myocardial infarction, and cardiac ischemia-reperfusion injury (Lesnefsky et al. 2017; Rosca and Hoppel 2013) . Both mitochondrial and nuclear DNA mutations of ETC and OXPHOS proteins have been associated with various cardiomyopathies (Meyers et al. 2013) . Considering the significance of mitochondrial function in the cardiovascular aging, in vitro high throughput functional tests of isolated cardiac mitochondria could identify the specific functional deficits and underlying mechanisms, and provide screening tools for potential therapeutic agents.
Seahorse XFe24 is high throughput technique for determination of mitochondrial respiratory function by simultaneously measuring oxygen consumption rate (OCR) and extracellular proton flux in the adherent cells. Recently, methodologies have been developed to measure the OCR in the isolated mitochondria from various organs and tissue biopsies (Boutagy et al. 2015; Rogers et al. 2011) . OCR measurements in the isolated mitochondria allow the researchers to determine the direct effects of pharmacological agents on the mitochondrial respiration by excluding the potential cellular signaling mechanisms influencing the mitochondrial function. In the present study, we optimized the method to measure respiratory function in the isolated cardiac mitochondria from mouse using seahorse XFe24. Using this optimized protocol, researchers can measure the effects of various therapeutic agents or antioxidants or transgenic mice on respiration in isolated mitochondria in vitro. Furthermore, studies may be designed to understand the impact of interventions like calorie restriction and exercise on cardiovascular aging. Thus, there are numerous research applications in cardiovascular aging for the proposed protocols to test respiratory function in isolated mitochondria.
First, measurements of respiration in isolated mitochondria from mouse liver and rat heart tissues utilizing XFe24 were reported in 2011 (Rogers et al. 2011) . Similarly, Das et al. reported standardized coupling and electron flow assays and identified respiratory defects in the isolated cardiac mitochondria from aged mice (Das and Muniyappa 2013) . However, previous reports lack the details necessary for isolating mitochondria, designing the functional assay, and analyzing the various aspects of mitochondrial respiration. Here, we report the detailed steps for isolating and purifying the mitochondria from the mouse heart which could be easily adapted for mitochondrial isolation from other tissues. We also provided the experimental design and analysis of data for assaying mitochondrial respiration function. We standardized our protocol with lower reaction volumes than the previously reported and validated our protocol with respiratory measurements made in isolated cardiac mitochondria from the mice. Thus, the present manuscript provides the first detailed protocol to make the respiratory functional measurements in the isolated mouse cardiac mitochondria using Seahorse XFe24 Analyzer.
Materials and methods
Animal procedures and protocols were performed in accordance with institutional and federal guidelines. All procedures from this study have been approved by the Institution of Animal Care and Use Committee (IACUC) at Tulane University School of Medicine.
Mitochondrial isolation
Mitochondrial isolation protocol was standardized in our laboratory and developed from previously published protocols (Kristian 2010; Sordahl 1984) . Perform all the steps on ice.
Isolation of mitochondria from mouse hearts 1. Anesthetize the mouse with isoflurane (VETOne, ID, USA). Tape the arms down on paper towels. Make an incision in the mouse at the abdomen and cut the skin to the top of the thorax. Use tweezers to lift the sternum and cut away the diaphragm and the ribcage to expose the heart. 2. Remove the heart and place in 5 mL of mitochondrial isolation medium (IM) on ice. Press with force to eject the blood from the chambers. Remove the aorta and atrium from the heart and cut the ventricles into three to four large pieces. 3. Transfer the tissue to a separate petri dish with fresh IM (5 mL), and chop into fine pieces with small scissors. 4. Transfer the minced tissue into the glass homogenizer along with the IM (5 mL). Perform 15 strong strokes with 4 turns on ice; then, transfer the homogenate into a 30-mL polycarbonate centrifuge tube. Care should be taken to prevent the negative pressure during lifting of the glass rod. 5. Centrifuge the homogenate at 27,000×g for 10 min at 4°C (DuPont Instruments, DE, USA). 6. Discard the supernatant and gently resuspend the pellet in 5 mL IM by mixing 10-20 times with a 5-mL pipette. 7. Centrifuge the solution at 500×g for 5 min at 4°C (Eppendorf, Hamburg, Germany). 8. Transfer the supernatant to a separate 30-mL polycarbonate centrifuge tube, and centrifuge at 10,000×g for 6 min at 4°C. 9. During this spin, prepare the required amount of 40, 24, and 15% Percoll solutions diluting 100% Percoll in IM. Add 3.5 mL of 24% Percoll to a new centrifuge tube. Add 4.5 mL of 40% Percoll slowly at the bottom of the centrifuge tube, beneath the 24% Percoll. A visible interface should be seen between the concentration gradient layers. 10. Remove the supernatant and resuspend the pellet in 3.5 mL of 15% Percoll (Mix gently 10-20 times each sequentially with 5-and 1-mL pipette).
Slowly layer this mitochondrial suspension on top of the 24% Percoll. Visible interfaces should be observed between the three Percoll gradient solutions. 11. Centrifuge at 30,000×g for 8 min at 4°C. Mitochondrial layer will be observed between the 24 and 40% Percoll layers. Collect the mitochondrial layer using a 5-mL BD syringe with spinal needle (approximately 3-5 mL suspension). Transfer the mitochondrial suspension into a new centrifuge tube with 5 mL of IM. Gently mix the suspension 10-20 times using the 5-mL pipette. 12. Centrifuge the mitochondrial suspension at 16,000×g for 10 min at 4°C. 13. A loose pellet (or small multiple pellets) will be observed at the bottom of the tube. Use 5mL-, 1mL-, and 200-μL pipettes to remove the supernatant and leave some supernatant above the pellet without disturbing the pellet. Add 0.5 mL of BSA diluted in IM (10 mg/mL) to the pellet. Tap the tube to dislodge the pellet into the BSA solution. Add 4.5 mL of IM and gently mix the suspension 10-20 times using the 5-mL pipette. 14. Centrifuge the solution at 7000×g for 10 min at 4°C. Discard the supernatant. Remove the supernatant and resuspend the mitochondria in 50 μL of IM without BSA. Gently mix the pellet suspension 10-20 times using the 100-μL pipette. Take required amount of the mitochondrial solution for protein quantification. Immediately double the mitochondrial suspension using IM (with BSA) and gently mix with pipette. Keep the mitochondria on ice to be used within 4 h. Further, experiments from 5 to 10 mice for each group is recommended for accuracy of the observations. 9. For representative images, point-point or mid-point data plots of a single experiment may be generated using the Agilent Seahorse analysis software. In addition, cumulative data from all the experiments may be processed offline and graphs can be generated by plotting software such as GraphPad Prism (Figs. 1, 2, and 3).
Notes

Mitochondrial isolation
1. This isolation procedure and volumes of reagents are standardized for isolation of mitochondria from one mouse heart. Pooled isolations from multiple hearts may need relative increase in reagent volumes with gentle homogenization of one mouse heart at a time. 2.
Step 7 can be repeated and the pooled supernatant can be used in step 8 for higher mitochondrial yields. 3. Prepare the required amount of fresh IM and 100%
Percoll every week and store them at 4°C. Check for the pH before starting the mitochondrial isolation and adjust the pH with 1 N KOH. Note that mitochondrial solutions contain high potassium representing intracellular potassium concentration. We observed poor mitochondrial yield and quality even with 2-week-old 100% Percoll solution (stored at 4°C). 4. Try to follow the suggested number of pipetting steps when resuspending the mitochondrial pellet at various steps. A high number of pipetting steps can physically damage the mitochondrial membranes. Tissue pieces may be observed at step 6 but they are discarded in step 8. While resuspending the mitochondrial pellet at step 8, even after pipetting gently for 20 times, we observed visible clumps of mitochondria. However, these clumps of mitochondria do not affect the mitochondrial yield as these pellets will reach the same layer as the individual mitochondria during the Percoll gradient centrifugation. 5. Prepare 40, 24, and 15% Percoll dilutions fresh every day. Vortex the solutions for at least 30-60 s after mixing the IM and 100% Percoll in the required quantities. 6. Low amount of mitochondrial layer between the 40 and 24% Percoll layers indicates a poor quality of 100% Percoll solution. During the collection of the mitochondrial layer, care should be taken so that the material in the 40% Percoll layer or in the interphase from 15 and 24% Percoll (which may contain nuclei and other cell organelles) is not drawn out contaminating the mitochondrial layer. 7. Mix the mitochondrial solution gently (10-20 times with 100-μL/1-mL pipette) whenever it is used (either for protein assay or for diluting and loading the mitochondria for the XFe24 assay). Squirting the mitochondria through narrow pipette tip or pipetting with force may rupture the mitochondria.
Seahorse XFe24 experiment
1. Overnight incubation of the cartridges in the calibration buffer at 37°C in a non-CO 2 incubator is highly recommended.
2. After the completion of the run, monitor the pH changes by selecting pH on Y2-axis in the overview mode. It helps to find out about any abnormal changes in pH during the assay. Ideally, the pH should be between 7 and 7.5 throughout each measurement during the assay (depends on the pH of the MAS used). 3. Observe the plate for mitochondrial attachment both after the microplate centrifugation step and after assay completion. OCR measurements from the wells with excessive attachment of mitochondria to the wall prior to or after the assay could be abnormal and may be represented as outlier. 4. Prepare 2× MAS and adjust pH to 7.4 using potassium hydroxide store at 4°C. Use 2× MAS to prepare pyruvate, malate stocks along with ADP. with pyruvate and malate and adjust the pH to 7.4 with KOH. 6. Prepare the stock solutions of drugs in 95% alcohol (10 mmol/L for oligomycin, FCCP and antimycin, and 2 mmol/L for rotenone) and aliquot them (25 or 50 μL) and store them in − 20°C. Use fresh aliquots to prepare the working solutions. Prepare the working drug solutions (oligomycin, FCCP, and antimycin/rotenone) in required quantities freshly every day in the pH-adjusted MAS with pyruvate and malate (checking pH of drug solutions is not required). 7. During data analysis, always consider both midpoint and point-to-point OCR data for assay standardization and for identifying any well with Boutlier^OCR measurements.
8. For OCR measurements after ADP supplementation, it is ideal to select the optimal ADP concentration and the measurement time such that the increased OCR is steady or exhibits a minimal decrease throughout the measurement period. We recommend 3 to 6 min of measuring time with an ADP concentration ranging from 1 to 5 mmol/L. 9. Though previous studies suggested basal OCR values between 100 and 200 pmol/min and state III (after ADP addition) within 1600-1800 pmol/ min, in our experiments, even basal OCR between 300 and 400 pmol/min showed robust responses to drugs as long as the state III respiration does not cross 1800 pmol/min. As day-to-day protein quantity and quality may vary, basal OCR values may be less than 100 (sometimes between 40 and 60 pmol/min), which may result in poor responses to drugs or increase the technical variation. 10. As the entire experiment, including mitochondrial isolation and Seahorse assay, takes a minimum of 6 to 8 h (for two Seahorse assays), prior planning and reagent preparation are required for consistent results. As such, we always run two Seahorse assays with isolated mitochondria (takes 3 to 4 h total time). Typically, we use the second plate of isolated mitochondria for replicating the first plate. 11. As previous studies reported the existence of two di fferent mitochondrial populations in cardiomyocytes depending on the position in the cells: intrafibromyolar (IFM) and subsarcolemmal (SSM) mitochondria. We predict our isolation protocol contains both types of mitochondrial populations, so any conclusions drawn must be applied to the whole cardiac mitochondria instead of a specific population.
